EDN1 and pulmonary arterial hypertension: An increase in ET-1 is associated with the pathological progression of HAPE and severity of pulmonary hypertension in humans, as it was shown that the ET-1 receptor antagonist proved to be efficacious against pulmonary hypertension [16, 21].